Several studies have demonstrated the presence of lymphomaassociated chromosomal translocations in blood samples of healthy adults using sensitive reverse transcription-PCR (RT-PCR) assays. The t(14;18) translocation (Bcl-2-IgH), which is the most common genetic aberration in lymphoid malignancies (90% in follicular lymphoma and 20-30% in diffuse large B-cell lymphomas), is found in circulating cells in up to 60% of healthy individuals by very sensitive PCR techniques. Furthermore, several studies clearly showed an age-dependent increase in the prevalence of circulating t(14;18)-positive cells that could be related to the environmental exposure to carcinogens, pesticides and excessive smoking. Similarly, BCR-ABL sequences derived from the t(9;22) Philadelphia translocation could be demonstrated in healthy persons.
The t(2;5)(p23;q35) is one of the most common cytogenetic abnormalities in Anaplastic Lymphoma Kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). 1 This translocation results in fusion of the genomic DNA of two genes, NPM on chromosome 5 and ALK on chromosome 2. This leads to the NPM-ALK fusion gene on the derivative chromosome 5, and to transcription of the chimeric NPM-ALK fusion gene. Translocation involving the ALK gene is found in 90% of paediatric ALCL cases 2 but only in 55% of adult ALCL, 3 raising the hypothesis that this chromosomal abnormality might occur in utero. Previous studies already demonstrated that healthy adults carried NPM-ALK-positive cells in peripheral blood and NPM-ALK-negative tissues. 4, 5 However, their presence has never been investigated in healthy newborns. Here we report the prevalence and the level of NPM-ALK transcripts in a series of 103 umbilical cord blood samples obtained from healthy newborns, using a real-time quantitative-PCR (RQ-PCR) approach that enabled us to detect circulating NPM-ALK-positive cells with a sensitivity of 10 À5 (see Supplementary Information for more detailed information). NPM-ALK transcripts were demonstrated in 2 of 103 analysed cord blood samples, which is a prevalence of 1.95%. The normalized copy numbers (NCNs) being expressed as copy numbers of NPM-ALK per 10 4 copies ABL, between two and six NCNs, were detected in the two PCR-positive samples. Blind re-checking test by another laboratory (C. Damm-Welk, Germany) was applied to these two positive cases along with 11 negative ones and gave concordant results.
We could assume that the normalized NPM-ALK copy numbers we detected corresponded approximately to 10 Other studies have already reported NPM-ALK-positive cells in normal individuals. 4, 5 However, even if the prevalence was high, the number of positive cells was lower than in our series. Trü mper et al. 4 were the first to report that 48% of healthy adults (14 out of 29) carried NPM-ALK-positive cells in peripheral blood. The RT-PCR assay based on hybridization of RT-PCR products to an internal breakpoint-specific oligonucleotide had a sensitivity of 10 À6 . But even though the technique was not quantitative, the failure to consistently demonstrate NPM-ALK in positive cases, when the number of the input cells fell below 10 5 cells, suggested a very low proportion of NPM-ALK-positive cells close to 10 À6 , compared with 10 À5 in our series. Another study 5 supported the existence of rearrangements in non-neoplastic bystander cells, showing the presence at a very low level of the NPM-ALK fusion transcripts in almost twothirds of non-neoplastic lymphoid tissues (lymph nodes and spleen), ALK-negative ALCL and Hodgkin's disease, using a very sensitive RQ-PCR assay at 10
À7
. The level of NPM-ALK transcripts in these cases, normalized by dividing the average NPM-ALK value by the average GAPDH value, was very low (5.10 À5 , equivalent to 0.5 NCNs of NPM-ALK using our normalisation method). In addition, these authors also observed a weak positivity for the ATIC-ALK fusion transcript, in only one reactive tissue sample. They hypothesized that this could explain why this specific fusion transcript is rarely observed in ALK-positive ALCL cases.
Whether individuals with circulating t(2;5)-positive cells are at an increased risk of developing ALCL remains an open question. Furthermore, it is not clear what kind of cell subsets carries the translocation. But, if this chromosomal abnormality is present in T lymphocytes, this could suggest that in utero t(2;5) translocation might initiate a multi-step process of lymphomagenesis, explaining why ALK-positive cases are much more prevalent in paediatric ALCL than in adults. It is well known that multiple mutational hits at oncogenes and tumour suppressor genes are necessary to promote malignant growth, in agreement with the classical 'two-hit' model of Knudson for non-inheritable cancers in childhood. It is therefore conceivable to find single genetic changes such as the t(14;18), t(9;22) and t(2;5) translocations at low frequencies in normal volunteers without the development of malignancies. Our findings exceeding the reported annual incidence rate of ALCL in children, of 1.2 per million supported that ALK-positive ALCL is a minimal two-step model and requires a second and independent genetic event for clinically overt lymphoma development. The complicated rearrangement machinery that lymphocytes use to generate antibody and T-cell receptor diversity may make these cells more prone to 'random' translocations that would represent the first hit. In addition, both fetal metabolism (for example, xenobiotic enzymes) and maternal exposure to carcinogens such as smoke would have a role in the level of chromosome aberrations observed in cord blood samples. This theory is already accepted in paediatric leukemias because of molecular biological evidence indicating that most cases of acute leukaemia in infants and children are indeed initiated in utero by chromosomal and genetic alterations. 7 The second hit could be related to a dysregulated immune response subsequent, for instance, to common infectious exposure in the first years of life that, in the case of children with preexisting 'abnormal' clones, could result in the emergence of a lymphoma. This could explain why ALK-positive ALCLs are mainly observed in children.
In this study, we show for the first time that t(2;5)-positive cells are present in umbilical cord blood samples. The presence of such fusion gene-bearing cells in newborns is well known for chromosomal translocations characteristic of paediatric leukaemias but has never been described, to the best of our knowledge, for fusion genes involved in paediatric lymphomas. These cells that will remain silent or covert in the absence of additional postnatal genetic hits could be premalignant clones of ALK-positive ALCL, if promotional exposures and/or associated secondary genetic events occur. Additionally, these data raise concerns about the use of stored cord blood for transplantation purposes, as some authors recently reported cases with donor cell-derived leukaemia following cord blood transplantation. 8 Our results also prompt to be cautious in PCR-based monitoring of minimal residual disease in NPM-ALK-positive ALCL. Department of Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany E-mail: laurence.lamant@inserm.fr 6 First co-authors.
